Eva Hoster

University Hospital, LMU Munich

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Ellen Leich

University of Würzburg

GERMANY

View details

Gilles Salles

Lymphoma Service, Chief

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Andreas Hüttmann

Universität Duisburg-Essen

GERMANY

View details

Aristoteles Giagounidis

Head of department

Katholisches Klinikum Koblenz

GERMANY

View details

Marion Subklewe

LMU University Hospital

GERMANY

View details

Konstantin Hellwig

University of Erlangen-Nuremberg

GERMANY

View details

Viktoria Blumenberg

Klinikum der Universität München

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eva Hoster

Research Interests

Explore related searches

Contact this professor

Articles (10)

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).

Collaborators (7)

Ellen Leich

Gilles Salles

Andreas Hüttmann

Aristoteles Giagounidis

Marion Subklewe

Konstantin Hellwig

Viktoria Blumenberg

Make your next move.